Methylene blue and G6PD deficiency: the test that comes first

What G6PD does

Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme that helps red blood cells protect themselves from oxidative damage. Red blood cells carry oxygen all day and are constantly exposed to reactive molecules, and G6PD keeps their defenses topped up.

When the enzyme is low, red blood cells cope fine most of the time. Under extra oxidative stress, such as certain medicines, infections or eating fava beans, they can break apart faster than the body can replace them. MedlinePlus Genetics calls this hemolytic anemia.

Who is likely to carry it

MedlinePlus Genetics estimates that about 400 million people worldwide have G6PD deficiency, and many never show signs. It is most common in people with ancestry from parts of Africa, Asia, the Mediterranean and the Middle East, and it affects about 1 in 10 African American males in the United States.

The gene sits on the X chromosome. Males have one X, so a single altered copy is enough to cause deficiency. Females have two, and many with one altered copy are still affected because of how X chromosomes are switched off in different cells. That makes results in women a little harder to interpret.

Why methylene blue is a specific concern

Methylene blue's FDA-approved use is treating methemoglobinemia, a blood disorder, in hospital. Its prescribing information lists G6PD deficiency as a contraindication and warns that people with the deficiency are at risk of severe hemolysis and severe anemia, which may need a blood transfusion. The label also notes that the breakdown can be delayed by a day or more, and that the drug may not even work in these patients.

Lower oral doses used for wellness have not been studied in people with G6PD deficiency. Without evidence of safety, the label contraindication is the guide we follow.

Why no symptoms is not reassurance

Many people with G6PD deficiency have taken common medicines, eaten fava beans or had infections without trouble, or with only mild episodes they put down to something else. The severity depends on the specific variant and the trigger. A history of never having had a reaction does not rule out a problem with a new oxidizing medicine.

How screening works

G6PD activity is measured with a simple blood test. Your clinician will advise on testing, which is priced separately from the treatment. A quantitative result, which reports the actual enzyme activity, is more informative than a simple positive or negative screen, particularly for women.

Testing is best done when you are well. Results can read falsely normal soon after a hemolytic episode or a blood transfusion, because younger red blood cells carry more enzyme.

What happens with your result

• Deficient result: methylene blue will not be prescribed, and you will get information on other medicines and foods to discuss with your clinicians
• Intermediate result, more common in women: your clinician will usually advise against methylene blue or discuss the uncertainty in detail
• Normal result: methylene blue may be considered, subject to the rest of the safety review, especially your medicine list
• Any result: keep a record and share it with future prescribers

Other triggers to know about

MedlinePlus Genetics lists infections, certain antibiotics and antimalarial drugs, and fava beans as common triggers. Pharmacists keep detailed lists of medicines to avoid or use with caution. If you find out you have G6PD deficiency, it is worth telling every clinician and pharmacist you see.

Family history is a useful clue

Because G6PD deficiency is inherited, relatives often share it. If a brother, father, uncle or grandparent has been told they react to certain antibiotics or antimalarial drugs, had jaundice as a newborn that needed treatment, or has a known G6PD diagnosis, mention it. Newborn jaundice is a common first sign of the deficiency, so asking parents about your own early months can also help. None of this replaces a blood test, but it shapes how your clinician reads the result.

Warning signs of hemolysis

Seek urgent medical care if you notice dark, tea-colored or red urine, yellowing of the skin or eyes, unusual paleness, new fatigue, shortness of breath or a racing heart, especially within a few days of starting a new medicine. Methylene blue also turns urine blue or green, which is expected, so the color change to watch for is dark brown or red.

The rest of the safety picture

G6PD screening is one of two non-negotiable checks. The other is a full medicine review, because methylene blue can cause serotonin syndrome with many antidepressants and other drugs. HealifyMD methylene blue is a compounded oral preparation from a licensed U.S. pharmacy; compounded medicines are not FDA-approved, and this use is off-label. The price is from $149/month, or $299 for 3 months ($100/month), confirmed at your eligibility review, with labs priced separately.